IDAHO IMMUNIZATION PROGRAM

2019-2020 Influenza Vaccine

September 2019

Important information for health care providers enrolled in the Idaho Immunization Program (IIP)

Recommendations

The Advisory Committee on Immunization Practices (ACIP) recommends annual influenza vaccination for **all persons aged 6 months or older** who do not have contraindications.

Balancing considerations regarding the unpredictability of timing of onset of the influenza season and concerns that vaccine-induced immunity might wane over the course of a season, it is recommended that vaccination should be offered by the end of October. Children aged 6 months through 8 years who require 2 doses (see algorithm on page 2) should receive the first dose as soon as the vaccine becomes available to allow the second dose (which must be administered ≥4 weeks later) to be received by the end of October. During the influenza season, vaccination should be offered as long as influenza viruses are circulating and unexpired vaccine is available. In addition, to avoid missed opportunities for vaccination, providers should offer vaccination during routine health care visits and hospitalizations to unvaccinated persons.

2019-2020 Influenza Vaccine Composition

The U.S. influenza quadrivalent vaccines for 2019-2020 will contain:

- A/Brisbane/02/2018 (H1N1)pdm09–like virus;
- A/Kansas/14/2017 (H3N2)–like virus;
- B/Colorado/06/2017-like virus (Victoria lineage); and
- B/Phuket/3073/2013-like virus (Yamagata lineage).

Presentations Available from the IIP for Pediatric Use

TRADE NAME		*MANUFACTURER*	*PRESENTATION*	*AGE GROUP*
Fluzone®	Quadrivalent	Sanofi Pasteur	0.25mL pre-filled syringe	6-35 months
Fluzone®	Quadrivalent	Sanofi Pasteur	0.5mL pre-filled syringe	≥ 6 months
Fluzone®	Quadrivalent	Sanofi Pasteur	0.5mL single dose vial	≥ 6 months
Fluzone®	Quadrivalent	Sanofi Pasteur	5.0mL multi-dose vial	≥ 6 months
Fluarix®	Quadrivalent	GlaxoSmithKline	0.5mL pre-filled syringe	≥ 6 months
FluLaval®	Quadrivalent	GlaxoSmithKline	0.5mL pre-filled syringe	≥ 6 months
FluLaval®	Quadrivalent	GlaxoSmithKline	5.0mL multi-dose vial	≥ 6 months
Flucelvax®	Quadrivalent	Seqirus	0.5mL pre-filled syringe	≥ 4 years
FluMist®	Quadrivalent	AstraZeneca	0.2mL pre-filled single-use intranasal sprayer	≥ 2 years

Children aged 6 through 35 Months

Children aged 6 through 35 months may receive one of three products licensed for this age group and provided by the IIP. The appropriate dose volumes for each of these vaccines differ for this age group. For these vaccines, children aged 6 through 35 months may receive either 0.25mL per dose or 0.5mL per dose of Fluzone® Quadrivalent, or 0.5mL per dose of Fluarix® Quadrivalent, or FluLaval® Quadrivalent.

These are the only influenza products licensed for this age group available through the IIP. Care should be taken to administer an age-appropriate volume for each dose. The needed volume may be administered from an appropriate pre-filled syringe, a single dose vial, or multi-dose vial, as supplied by the manufacturer.

Children aged 6 months through 8 years

Determination of the number of doses needed is based on 1) the child's age at the time of the first dose of 2019–20 influenza vaccine and 2) the number of doses of influenza vaccine received in previous influenza seasons£:



*The two doses need not have been received during the same season or consecutive seasons.

† Doses should be administered at least 4 weeks apart.

£ For children aged 8 years who require 2 doses of vaccine, both doses should be administered even if the child turns age 9 years between receipt of dose 1 and dose 2.

Alternate Text: Children aged 6 months through 8 years who have previously received ≥2 total doses of trivalent or quadrivalent influenza vaccine before July 1, 2019 require only 1 dose for 2019-20. The two previous doses need not have been given during the same season or consecutive seasons. Children in this age group who have not previously received ≥2 doses of trivalent or quadrivalent influenza vaccine ≥4 weeks apart before July 1, 2019, or whose previous influenza vaccination history is unknown, require 2 doses for the 2019-20 season. The interval between the 2 doses should be at least 4 weeks. Two doses are recommended even if the child turns age 9 years between receipt of dose 1 and dose 2.

For additional information please refer to *MMWR* / Recommendations and Reports / August 23, 2019 / 68(3);1-21 or visit https://www.cdc.gov/mmwr/volumes/68/rr/pdfs/rr6803-H.pdf

Supply

Early each spring the IIP requests seasonal influenza vaccine doses from the Centers for Disease Control and Prevention (CDC) based on provider pre-book requests, population estimates, estimated vaccine uptake, and available funding. The number of doses IIP receives is dependent upon CDC contracts with vaccine manufacturers, ACIP recommendations, and vaccine production volume. The IIP cannot guarantee production and distribution of seasonal influenza vaccine.

Seasonal influenza vaccine will be allocated to IIP in waves during August through December as it becomes available and the IIP will distribute the influenza vaccine providers have requested as soon as possible. Providers should expect to receive vaccines requested during the 2019-2020 Seasonal Influenza Vaccine Pre-book, however, the number of doses and presentations available at any particular time may vary.

The availability of FluMist® Quadrivalent, live attenuated influenza vaccine (LAIV4) is very limited because of manufacturing restraints and the IIP's original request to CDC was reduced by 75%. Consequently, the IIP will be replacing some pre-book FluMist® doses with other quadrivalent, inactivated influenza vaccines.

Ordering

2019-2020 seasonal influenza vaccine can be requested from the IIP through the Immunization Reminder Information System (IRIS) beginning September 5, 2019. This is new functionality in IRIS and influenza vaccine is no longer ordered through the Manage Orders screen. Instead, it is requested through the new **Prebook Request Status** screen found by clicking the *manage prebookings* under **Inventory** in the left-side menu, selecting a vaccine presentation and then clicking the *Request Vaccine* button. The guidelines for requesting influenza vaccine from the IIP can be found in the IIP Provider Resource Binder or at the following link: Requesting Influenza Vaccine Guidance.

- Request influenza vaccine as needed; influenza vaccine requests do not need to follow your organization's ordering frequency.
- Request only influenza vaccine doses, brands, and presentations allocated to your organization in IRIS.
- Keep doses of influenza vaccine administered current in IRIS. A physical vaccine count is not required to request influenza vaccine, but on-hand influenza inventory counts will be reviewed during the season as vaccine orders are processed.

Multi-dose Vials (MDV) of Influenza Vaccine

The IIP will be supplying two influenza vaccines in multi-dose vials (MDV). After the MDV has been used for the first time, the Fluzone® Quadrivalent 0.5mL MDV may be used until the expiration date printed on the vial. The **FluLaval® 0.5mL MDV may only be administered until 28 days after the first use**. Please document the "beyond use date," or BUD (28 days from the date the MDV of FluLaval® is initially opened) on the label along with the initials of the person noting the date.

Vaccine Information Statements

Vaccine Information Statements (VISs) are available for both inactivated and live, intranasal influenza vaccine. The edition dated 08/15/19 should be used. The VISs are available online at: https://www.cdc.gov/vaccines/hcp/vis/vis-statements/flu.pdf and https://www.cdc.gov/vaccines/hcp/vis/vis-statements/flulive.pdf

PEDIATRIC INFLUENZA VACCINE

available from the Idaho Immunization Program
for the 2019-2020 season*

Vaccine	Trade Name	Manufacturer	Presentation	Mercury Content (mcg Hg/0.5mL dose)	Age Group	Number of Doses	Route	NDC	CPT Code	CVX Codes (for electronic exports)
IIV4	Fluzone® Quadrivalent	Sanofi Pasteur	0.25mL pre-filled syringe	0	6-35 months	1 or 2	IM**	49281-0519-25	90685	161
			0.5mL pre-filled syringe	0	≥ 6 months	1 or 2	IM**	49281-0419-50	90686	150
			0.5mL single dose vial	0	≥ 6 months	1 or 2	IM**	49281-0419-10	90686	150
			5.0mL multi-dose vial	25	≥ 6 months	1 or 2	IM**	49281-0631-15	90688	158
IIV4	Fluarix® Quadrivalent	GlaxoSmithKline	0.5mL pre-filled syringe	0	≥ 6 months	1 or 2	IM**	58160-0896-52	90686	150
	FluLaval® Quadrivalent		0.5mL pre-filled syringe	0	> 6 months	1 or 2	IM**	19515-0906-52	90686	150
			5.0mL multi-dose vial	<25	> 6 months	1 or 2	IM**	19515-0897-11	90688	158
ccIIV4	Flucelvax® Quadrivalent	Seqirus	0.5mL pre-filled syringe	0	≥ 4 years	1 or 2	IM**	70461-0319-03	90674	171
LAIV4	FluMist® Quadrivalent	AstraZeneca	0.2mL pre-filled single-use intranasal sprayer	0	≥ 2 years	1 or 2	NAS	66019-0306-10	90672	149

Abbreviations: NDC=National Drug Code; IIV4=inactivated influenza vaccine, quadrivalent; ccIIV4=inactive influenza vaccine, quadrivalent, cell culture based; LAIV4=live attenuated influenza vaccine, quadrivalent; IM=intramuscular injection; NAS=intranasal.

* Immunization providers should check Food and Drug Administration--approved prescribing information for 2019-20 influenza vaccines for the most complete and updated information, including, but not limited to indications, contraindications, and precautions. Package inserts for U.S.-licensed quadrivalent influenza vaccines are available at https://www.fda.gov/vaccines-blood-biologics/approved-products/vaccines-licensed-use-united-states. Availability of specific products and presentations might change and differ from what is described in this table and text of this resource.

** For adults and older children, the preferred site of vaccination is the deltoid muscle. Infants and young children should be vaccinated in the anterolateral thigh. Additional specific guidance regarding site selection and needle length for intramuscular administration is provided in the Advisory Committee on Immunization Practice Guidelines for Immunization available at http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6002a1.htm.

IDAHO IMMUNIZATION PROGRAM

For additional information regarding 2019-2020 seasonal influenza vaccine, please refer to the Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report / Recommendations and Reports / August 23, 2019 / 68(3);1-21 or visit https://www.cdc.gov/mmwr/volumes/68/rr/pdfs/rr6803-H.pdf.

INFLUENZA VACCINE DOSING ALGORITHM FOR CHILDREN AGED 6 MONTHS THROUGH 8 YEARS£

For the 2019-2020 influenza season



*The two doses need not have been received during the same season or consecutive seasons.

† Doses should be administered at least 4 weeks apart.

£ For children aged 8 years who require 2 doses of vaccine, both doses should be administered even if the child turns 9 years of age between receipt of dose 1 and dose 2.

Alternate Text: Children aged 6 months through 8 years who have previously received ≥2 total doses of trivalent or quadrivalent influenza vaccine before July 1, 2019 require only 1 dose for 2019-20. The two previous doses need not have been given during the same season or consecutive seasons. Children in this age group who have not previously received ≥2 doses of trivalent or quadrivalent influenza vaccine ≥4 weeks apart before July 1, 2019, or whose previous influenza vaccination history is unknown, require 2 doses for the 2019-20 season. The interval between the 2 doses should be at least 4 weeks. Two doses are recommended even if the child turns age 9 years between receipt of dose 1 and dose 2.

For additional information refer to MMWR / Recommendations and Reports / August 23, 2019 / 68(3); 1-21 or https://www.cdc.gov/mmwr/volumes/68/rr/rr6803a1.htm?s_cid=rr6803a1_w

Advisory Committee on Immunization Practices, United States, 2019-2020 influenza season

IDAHO IMMUNIZATION PROGRAM